首页> 外文期刊>European urology >Oncologic outcome after extraperitoneal laparoscopic radical prostatectomy: midterm follow-up of 1115 procedures.
【24h】

Oncologic outcome after extraperitoneal laparoscopic radical prostatectomy: midterm follow-up of 1115 procedures.

机译:腹腔镜腹腔镜前列腺癌根治术后的肿瘤学结局:1115例手术的中期随访。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Although the first laparoscopic radical prostatectomy was performed in 1997, few midterm oncologic data have been published for the extraperitoneal procedure. OBJECTIVE: To determine the oncologic outcome of extraperitoneal laparoscopic radical prostatectomy (ELRP). DESIGN, SETTING, AND PARTICIPANTS: From 2000 to 2007, 1115 consecutive patients underwent ELRP for a localized prostate cancer at our department. Follow-up was scheduled and standardized for all patients and recorded into a prospective database. Median postoperative follow-up was 35.6 mo. INTERVENTION: All ELRP were performed by three surgeons at the Department of Urology, Hospital Henri Mondor, Creteil, France. MEASUREMENTS: Biochemical recurrence was defined by prostate-specific antigen level > or =0.2 ng/ml. RESULTS AND LIMITATIONS: In pN0/pNx cancers, postoperative stage was pT2 in 664 patients (59.5%), pT3 in 350 patients (31.4%), and pT4 in 77 patients (6.9%). Positive lymph nodes were reported in 24 patients (2.2%). Margins were positive in 16.1% and 34.6% of pT2 and pT3 cancers, respectively. Final Gleason score was <7 in 288 men (25.8%), =7 in 701 men (62.9%), and >7 in 126 men (11.3%). Overall prostate-specific antigen (PSA) recurrence-free survival was 83% at 5 yr. The 5-yr progression-free survival rates were 93.4% for pT2, 74.5% for pT3a, and 55.0% for pT3b tumors, respectively. Multivariate Cox model showed that PSA, Gleason score, pT category, nodal status, and surgical margins were significant independent predictors of biochemical recurrence-free survival. CONCLUSIONS: This assessment of oncologic results demonstrates that ELRP is a safe and effective procedure. On the basis of midterm follow-up data, the prognostic factors of PSA after ELRP failure are the same as those described previously in transperitoneal or open retropubic approaches. The oncologic results of ELRP also are in line with those reported with the use of the retropubic or the transperitoneal laparoscopic approaches.
机译:背景:尽管在1997年进行了首例腹腔镜前列腺癌根治术,但很少有关于腹膜外手术的中期肿瘤学数据发表。目的:确定腹膜外腹腔镜前列腺癌根治术(ELRP)的肿瘤学结局。设计,地点和参加者:从2000年到2007年,我科连续1115例患者因局部前列腺癌接受了ELRP。为所有患者安排了随访并进行了标准化,并将其记录在前瞻性数据库中。术后中位随访时间为35.6 mo。干预:所有ELRP均由法国Creteil亨利蒙多医院泌尿外科的三名外科医生进行。测量:生化复发定义为前列腺特异性抗原水平>或= 0.2 ng / ml。结果与局限性:在pN0 / pNx癌症中,术后分期为664例患者(59.5%)中的pT2、350例患者(31.4%)中的pT3和77例患者(6.9%)中的pT4。 24例患者报告淋巴结阳性(2.2%)。 pT2和pT3癌症的利润率分别为16.1%和34.6%。格里森(Gleason)最终得分在288名男性中为<7(25.8%),在701名男性中为7(62.9%),在126名男性中为7(11.3%)。总体前列腺特异性抗原(PSA)无复发生存率在5年时为83%。 pT2的5年无进展生存率分别为93.4%,pT3a为74.5%和pT3b肿瘤为55.0%。多元Cox模型显示PSA,Gleason评分,pT类别,淋巴结状态和手术切缘是无生化复发生存率的重要独立预测因子。结论:对肿瘤结果的评估表明,ELRP是一种安全有效的方法。根据中期随访数据,ELRP失败后PSA的预后因素与先前在经腹膜或耻骨后开放手术中描述的因素相同。 ELRP的肿瘤学结果也与使用耻骨后或腹膜后腹腔镜方法报道的结果一致。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号